Las Vegas, NV -- (SBWIRE) -- 01/02/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Ion Geophysical Corp(NYSE:IO), Meritor Inc(NYSE:MTOR), Keryx Biopharmaceuticals(NASDAQ:KERX), Celldex Therapeutics, Inc.(NASDAQ:CLDX)
Ion Geophysical Corp(NYSE:IO) was a volume gainer of 1.95 million shares and the average volume of the stock remained 1.51 million shares. The stock opened the session at $3.16 and finished at the end of the day at $3.30and the stock escalated 5.10%.The market capitalization of the stock remained 538.91 million. ION Geophysical Corporation provides planning and seismic processing services, software, and acquisition equipment to the energy industry worldwide. Its Solutions segment provides seismic data processing services for marine and land environments, reservoir solutions, onboard processing and quality control.
For How Long IO will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Meritor Inc(NYSE:MTOR) exchanged 1.93 million shares and the average volume remained 1.74 million shares. The stock closed the session at $10.43 with the gain of 2.25%. Meritor, Inc. designs, develops, manufactures, sells, markets, distributes, services, and supports integrated systems, modules, and components to original equipment manufacturers (OEMs) and the aftermarket for the commercial vehicle, transportation, and industrial sectors. The company was formerly known as ArvinMeritor, Inc. and changed its name to Meritor, Inc. in March 2011. Meritor, Inc. was founded in 1921 and is headquartered in Troy, Michigan.
Will MTOR Continue To Move Higher? Find Out Here
Keryx Biopharmaceuticals(NASDAQ:KERX) enhanced 1.41% and its closing price was $12.95. The volume of the stock was 1.94 million shares and the average volume remained 2.33 million shares. The market capitalization of the stock remained 1.07 billion. The beta of the stock remained 3.93. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
Why Should Investors Buy KERX After The Recent Gain? Just Go Here and Find Out
Celldex Therapeutics, Inc.(NASDAQ:CLDX) exchanged 1.89 million shares in the previous trading session, and its average trading remained 2.35 million shares. CLDX advanced 3.46% and it closed the trading at $24.21. The market capitalization of the stock remained 2.13 billion. Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
For How Long CLDX’s Gloss will Attract Investors? Find out via this report
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)